COVID‐19 and the clinical hematology laboratory

DOI Web Site Web Site Web Site 1 Citations
  • John L. Frater
    Department of Pathology and Immunology Washington University St. Louis MO USA
  • Gina Zini
    Hematology and Clinical Pathology Catholic University of Rome Rome Italy
  • Giuseppe d’Onofrio
    Hematology and Clinical Pathology Catholic University of Rome Rome Italy
  • Heesun J. Rogers
    Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH USA

Description

<jats:title>Abstract</jats:title><jats:p>The ongoing COVID‐19 pandemic originated in Wuhan, Hubei Province, China, in December 2019. The etiologic agent is a novel coronavirus of presumed zoonotic origin with structural similarity to the viruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Like SARS and MERS, COVID‐19 infection manifests most frequently with lower respiratory symptoms. A minority of patients progress to acute respiratory distress syndrome/ diffuse alveolar damage. In addition to its central role in the diagnosis of COVID‐19 infection, the clinical laboratory provides critical information to clinicians regarding prognosis, disease course, and response to therapy. The purpose of this review is to (a) provide background context about the origins and course of the pandemic, (b) discuss the laboratory's role in the diagnosis of COVID‐19 infection, (c) summarize the current state of biomarker analysis in COVID‐19 infection, with an emphasis on markers derived from the hematology laboratory, (d) comment on the impact of COVID‐19 on hematology laboratory safety, and (e) describe the impact the pandemic has had on organized national and international educational activities worldwide.</jats:p>

Journal

Citations (1)*help

See more

Report a problem

Back to top